Stemness Regulation in Prostate Cancer: Prostate Cancer Stem Cells and Targeted Therapy

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Dec 23

PMID 39711287

Authors

Hao Liang

Bin Zhou

Peixin Li

Xiaoyi Zhang

Shijie Zhang

Yaozhong Zhang

Shengwen Yao

Sifeng Qu

Jun Chen

Affiliations

Soon will be listed here.

Abstract

Background: Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression.

Objective: This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells.

Methods: After searching in PubMed and Embase databases using 'prostate cancer' and 'cancer stem cells' as keywords, studies related were compiled and examined.

Results: In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial-mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions.

Conclusion: A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Gimple R, Yang K, Halbert M, Agnihotri S, Rich J . Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer. 2022; 22(9):497-514. DOI: 10.1038/s41568-022-00486-x. View

Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K . Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016; 22(17):4505-16. PMC: 5010458. DOI: 10.1158/1078-0432.CCR-15-2956. View

Liu N, Mei L, Fan X, Tang C, Ji X, Hu X . Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett. 2016; 378(1):38-50. DOI: 10.1016/j.canlet.2016.05.010. View

David C, Massague J . Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018; 19(7):419-435. PMC: 7457231. DOI: 10.1038/s41580-018-0007-0. View

Liu Y, Yang M, Deng Y, Su G, Enninful A, Guo C . High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue. Cell. 2020; 183(6):1665-1681.e18. PMC: 7736559. DOI: 10.1016/j.cell.2020.10.026. View

Henrich S, McMahon K, Plebanek M, Calvert A, Feliciano T, Parrish S . Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner. J Extracell Vesicles. 2021; 10(2):e12042. PMC: 7775568. DOI: 10.1002/jev2.12042. View

Deng Z, Wu Y, Ma W, Zhang S, Zhang Y . Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015; 16:1. PMC: 4318439. DOI: 10.1186/s12865-014-0064-x. View

Li R, Liang J, Ni S, Zhou T, Qing X, Li H . A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010; 7(1):51-63. DOI: 10.1016/j.stem.2010.04.014. View

10.

Neiheisel A, Kaur M, Ma N, Havard P, Shenoy A . Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer. 2021; 150(5):727-740. DOI: 10.1002/ijc.33811. View

11.

Kaltschmidt C, Banz-Jansen C, Benhidjeb T, Beshay M, Forster C, Greiner J . A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers (Basel). 2019; 11(5). PMC: 6563002. DOI: 10.3390/cancers11050655. View

12.

Wang L, Zi H, Luo Y, Liu T, Zheng H, Xie C . Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells. Stem Cell Res Ther. 2020; 11(1):258. PMC: 7318403. DOI: 10.1186/s13287-020-01773-w. View

13.

Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B . Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2020; 589(7842):448-455. PMC: 7612440. DOI: 10.1038/s41586-020-03046-1. View

14.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

15.

Singh N, Ramnarine V, Song J, Pandey R, Padi S, Nouri M . The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021; 12(1):7349. PMC: 8692330. DOI: 10.1038/s41467-021-26901-9. View

16.

Brown G . Deregulation of All- Retinoic Acid Signaling and Development in Cancer. Int J Mol Sci. 2023; 24(15). PMC: 10419198. DOI: 10.3390/ijms241512089. View

17.

Stein M, Hussain M, Stadler W, Liu G, Tereshchenko I, Goodin S . A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2015; 14(1):22-7. PMC: 4698193. DOI: 10.1016/j.clgc.2015.09.010. View

18.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

19.

Jansson K, Tucker J, Stahl L, Simmons J, Fuller C, Beshiri M . High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Sci Rep. 2018; 8(1):17239. PMC: 6250716. DOI: 10.1038/s41598-018-35417-0. View

20.

Li X, Pham V, Tippin M, Fu D, Rendon R, Song L . Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019; 17(1):25. PMC: 6423783. DOI: 10.1186/s12964-019-0338-2. View